Shares of BioLife Solutions Inc (NASDAQ:BLFS) have received a consensus rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $22.33.

A number of brokerages recently commented on BLFS. BidaskClub downgraded shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a report on Friday, September 7th. B. Riley began coverage on shares of BioLife Solutions in a report on Thursday, June 7th. They issued a “buy” rating and a $14.00 price target for the company. Northland Securities reaffirmed a “buy” rating and issued a $18.00 price target on shares of BioLife Solutions in a report on Friday, August 10th. Maxim Group reaffirmed a “buy” rating and issued a $26.00 price target on shares of BioLife Solutions in a report on Wednesday, September 5th. Finally, TheStreet raised shares of BioLife Solutions from a “d” rating to a “c-” rating in a report on Tuesday, September 11th.

In related news, Director Joseph C. Schick sold 4,765 shares of the stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $25.96, for a total value of $123,699.40. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $259,600. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Rice sold 12,540 shares of the stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $12.89, for a total transaction of $161,640.60. Following the completion of the transaction, the chief executive officer now directly owns 152,057 shares of the company’s stock, valued at approximately $1,960,014.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 594,925 shares of company stock valued at $7,559,453. 38.50% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in BLFS. Casdin Capital LLC purchased a new stake in BioLife Solutions in the 2nd quarter worth about $11,410,000. Essex Investment Management Co. LLC raised its position in BioLife Solutions by 29.4% in the 2nd quarter. Essex Investment Management Co. LLC now owns 295,728 shares of the medical equipment provider’s stock worth $3,374,000 after purchasing an additional 67,182 shares during the period. Millennium Management LLC raised its position in BioLife Solutions by 32.3% in the 1st quarter. Millennium Management LLC now owns 241,470 shares of the medical equipment provider’s stock worth $1,234,000 after purchasing an additional 58,920 shares during the period. Renaissance Technologies LLC raised its position in BioLife Solutions by 644.2% in the 2nd quarter. Renaissance Technologies LLC now owns 206,900 shares of the medical equipment provider’s stock worth $2,361,000 after purchasing an additional 179,100 shares during the period. Finally, EAM Investors LLC raised its position in BioLife Solutions by 93.1% in the 2nd quarter. EAM Investors LLC now owns 182,911 shares of the medical equipment provider’s stock worth $2,087,000 after purchasing an additional 88,180 shares during the period. 27.77% of the stock is owned by hedge funds and other institutional investors.

Shares of BLFS traded up $0.37 during midday trading on Thursday, hitting $18.52. 348,484 shares of the company traded hands, compared to its average volume of 407,659. BioLife Solutions has a 52 week low of $4.63 and a 52 week high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.01. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.24%. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.20 million. sell-side analysts forecast that BioLife Solutions will post 0.15 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Recommended Story: Earnings Per Share

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.